Shire grabs FDA ok with blockbuster potential

Aug 24, 2018

The U.S. FDA has approved a first of its kind drug from Shire to treat patients suffering from a rare disease, hereditary angioedema (HAE), that causes swelling.

The drug, Takhzyro, is expected to bring in blockbuster sales for Shire. The approval is important to Japan’s Takeda Pharma, as it prepares to buy Shire for $62 billion.

Takhzyro is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with HAE, to help prevent attacks.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments